Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-15Clinical Trial Update: Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention [NA]
A completed clinical trial assessing safety and efficacy of Nerivio for migraine prevention has results posted.
-
FDA approval · 2023-03-10FDA Approved: TOPIRAMATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's original application for topiramate, making a generic version of the anti-seizure and migraine-prophylaxis medication av…
-
FDA approval · 2023-03-09FDA Approved: ZAVZPRET — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved the original application for Zavzpret (zavegepant) from Pfizer Inc. for the treatment of migraine.
-
FDA approval · 2023-03-08FDA Approved: TOPIRAMATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for Topiramate from Aurobindo Pharma Limited, confirming regulatory clearance for its generic Topi…
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis [Phase 4]
Phase 4 clinical trial evaluating topiramate, amitriptyline as monotherapy and in combination for migraine prophylaxis; status currently unk…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-07FDA Approved: TOPIRAMATE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for Topiramate submitted by NorthStar RxLLC. The approval indicates changes to the existing prod…
-
FDA approval · 2023-03-01FDA Approved: TOPIRAMATE — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s original ANDA for a generic Topiramate product.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Efficacy of Inhaled Cannabis for Acute Migraine Treatment [Phase 2]
Phase 2 clinical trial evaluating inhaled cannabis for acute migraine treatment has completed.
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) submitted by AbbVie Inc.
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie, expanding the NDA with additional regul…
-
FDA approval · 2023-02-17FDA Approved: UBRELVY — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for UBRELVY (ubrogepant), resulting in a label update for its use in treating acute migrain…
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine [Phase 3]
Phase 3 trial update on atogepant for prevention of chronic migraine, reporting efficacy, safety, and tolerability results.
-
FDA approval · 2023-02-08FDA Approved: DIHYDROERGOTAMINE MESYLATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for dihydroergotamine mesylate (ANDA 040453).
-
FDA approval · 2023-01-25FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approves a supplemental application for divalproex sodium submitted by Ajanta Pharma USA Inc.
-
FDA approval · 2023-01-19FDA Approved: SUMATRIPTAN — Original Application (Baxter Healthcare Corporation)
This FDA entry documents the original approval of sumatriptan by Baxter Healthcare Corporation for the acute treatment of migraine.
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: Efficacy of GONB in Patients of Migraine [Phase 4]
Phase 4 trial update evaluating the efficacy of GONB in patients with chronic migraine and headache has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Efficacy, Tolerability, and Safety Study of DFN-15 [Phase 3]
Phase 3 trial results for DFN-15 in migraine headache completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2) [Phase 4]
A Phase 4 trial evaluating the effect of a device closure in alleviating migraine associated with patent foramen ovale (PFO).
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches [NA]
Completed clinical trial evaluating Avulux Lenses as an aid to reduce migraine impact; results posted in 2023.
-
FDA approval · 2022-12-27FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for divalproex sodium from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Spectacle Tints and Thin-Films for Migraine [NA]
A terminated clinical trial at the University of Utah investigated spectacles with tints and thin-films for migraine/headache; results poste…
-
FDA approval · 2022-11-28FDA Approved: TOPIRAMATE — Original Application (Zydus Lifesciences Limited)
FDA approved Zydus Lifesciences Limited's Original Application for a generic Topiramate. Topiramate is used for epilepsy and migraine prophy…
-
FDA approval · 2022-11-21FDA Approved: TOPIRAMATE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for Topiramate (generic Topiramate) from NorthStar RxLLC under an ANDA.
-
FDA approval · 2022-11-16FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for divalproex sodium, authorizing changes to the approved generic product unde…
-
CLINICAL_TRIALS trial_result · 2022-10-31Clinical Trial Update: Eptinezumab in Adults With Migraine and Medication Overuse Headache [Phase 3]
Phase 3 trial update for eptinezumab in adults with migraine and medication overuse headache has completed.